A Randomized Phase 2 Study of Nivolumab Monotherapy Versus Nivolumab Combined With Ipilimumab in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor (GIST)
Phase of Trial: Phase II
Latest Information Update: 20 Jan 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 20 Jan 2018 Interim results (n=22) assessing safety and efficacy in advanced GIST patients, presented at the 2018 Gastrointestinal Cancers Symposium.
- 20 Dec 2016 Status changed from not yet recruiting to recruiting.
- 09 Sep 2016 New trial record